Ignite Creation Date:
2024-07-17 @ 11:43 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06491953
Status:
RECRUITING
Last Update Posted:
2024-07-09
First Post:
2024-07-01
Brief Title:
SGLT2-inhibitors on PC-AKI
Sponsor:
Shenyang Northern Hospital
Organization:
Shenyang Northern Hospital
Study Overview
Official Title:
Impact of SGLT2-inhibitors on Post Contrast Acute Kidney Injury in Acute Coronary Syndrome Patients Receiving Invasive Strategy
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Percutaneous coronary intervention PCI is one of the most common invasive strategies employed in the diagnosis and treatment of coronary artery disease CAD patients Invasive procedures necessitate the use of iodine-based contrast agents which could lead to post contrast acute kidney injury PC-AKI
Sodium-glucose cotransporter 2 SGLT-2 inhibitors as a class of oral antidiabetic medications function by inhibiting SGLT-2 preventing the reabsorption of filtered glucose by the kidneys and thereby increasing glucose excretion in urine In recent years a series of studies including EMPA-REG OUTCOME CREDENCE DAPA-CKD DECLARE-TIMI 58 and the CANVAS program have consistently demonstrated that SGLT-2 inhibitors not only effectively improve renal function and slow the progression of chronic kidney disease CKD but also significantly reduce the risk of cardiovascular adverse events Nevertheless due to their osmotic diuretic effect SGLT-2 inhibitors can lead to a reduction in renal blood volume within the early phase of application within two weeks temporarily augmenting the renal workload and resulting in a decrease in estimated glomerular filtration rate eGFR
Consequently there remains a need to ascertain the specific role of SGLT-2 inhibitors in the prevention of PC-AKI and provide evidence-based support for their application in this context
Sodium-glucose cotransporter 2 SGLT-2 inhibitors as a class of oral antidiabetic medications function by inhibiting SGLT-2 preventing the reabsorption of filtered glucose by the kidneys and thereby increasing glucose excretion in urine In recent years a series of studies including EMPA-REG OUTCOME CREDENCE DAPA-CKD DECLARE-TIMI 58 and the CANVAS program have consistently demonstrated that SGLT-2 inhibitors not only effectively improve renal function and slow the progression of chronic kidney disease CKD but also significantly reduce the risk of cardiovascular adverse events Nevertheless due to their osmotic diuretic effect SGLT-2 inhibitors can lead to a reduction in renal blood volume within the early phase of application within two weeks temporarily augmenting the renal workload and resulting in a decrease in estimated glomerular filtration rate eGFR
Consequently there remains a need to ascertain the specific role of SGLT-2 inhibitors in the prevention of PC-AKI and provide evidence-based support for their application in this context
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None